Data-driven healthcare company, Atropos Health, has announced a new agreement with Janssen Research & Development, LLC (Janssen), a Johnson & Johnson company, aimed at accelerating clinical development through real-world data analysis. This collaboration builds upon an existing partnership between the two companies.
Under the new agreement, data scientists from Atropos and Janssen will utilize Atropos’s software platform to analyze Janssen’s in-house real-world data sets. The goal is to gain insights that can inform clinical development strategies, such as optimizing trial design, understanding patient natural histories, and assessing outcomes in real-world patient populations. The collaboration will cover a broad range of therapeutic areas.
“Atropos Health’s core mission is to close the evidence gap for patients worldwide,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “We are thrilled to collaborate with Janssen R&D’s world-class data scientists to support efforts to generate insights that could help optimize and accelerate clinical trials.”
Atropos Health is a leader in rapid and rigorous evidence generation across research and clinical use. The company’s technology aims to accelerate clinical development and shorten the time to value. The Atropos Evidence Platform combines the Green Button Clinical Informatics Consult Service with cloud-based data integration within life science companies’ technology stack to generate evidence in just 48 hours. This evidence is stored in a private library, allowing life science companies to maximize their real-world data assets for various purposes, including hypothesis testing, protocol feasibility, cohort analysis, treatment pathways, patient journeys, and identifying unmet needs.
The evidence generated by Atropos Health can be produced from customers’ cloud-based in-house data platforms or through external data accessed via the Atropos Evidence Network. The network provides a secure mechanism for greater information access and study capabilities. All evidence in the network contains a Real World Fitness Score (RWFS), which indicates the fitness or suitability of the underlying data for a specific study. This allows life science companies to quickly identify “fit-for-purpose” data, shifting paradigms in data strategy and enabling faster analyses that can be validated with clinical perspectives.
The collaboration between Atropos Health and Janssen Research & Development demonstrates the increasing importance and value of real-world data analysis in clinical development. By harnessing the power of data-driven insights, researchers and healthcare professionals can optimize and accelerate the development of new treatments and therapies. Ultimately, this collaboration aims to improve patient outcomes and bridge the evidence gap in healthcare.